Latest Vycor Medical Inc. (VYCO) Headlines
Vycor Medical, Inc. President David Cantor to Be Interviewed Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Thu Jan 23, 6:15AM CST
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today that President David Cantor will interviewed live by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Vycor's NovaVision Unit Announces the Commercial Release of NeuroEyeCoach(TM) -- A Novel Saccadic Eye Training Therapy
Marketwire - Thu Jan 23, 6:00AM CST
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today that its wholly-owned subsidiary, NovaVision has launched the first commercial release of its new saccadic eye training therapy which will be marketed in the U.S. as NeuroEyeCoach(TM). The therapy is now available through the web site www.NeuroEyeCoach.com.
Vycor's NovaVision(R) Vision Restoration Therapy Awarded New Patent
Marketwire - Thu Oct 31, 7:31AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today it has been granted Australian patent # 2007277139 for its NovaVision(R) vision restoration technology. The new patent brings Vycor's total worldwide patent portfolio to 37 granted and 18 pending.
Vycor Medical Announces Planned Launch of First Commercially Available Internet-Based, Direct to the Patient Saccadic Eye Training Program
Marketwire - Tue Oct 15, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today its wholly-owned NovaVision subsidiary plans to launch a new "direct to the patient" saccadic eye training program to be marketed as NeuroEyeCoach(TM). The proprietary Internet-based program is expected to be commercially available by year-end 2013. Additionally, NeuroEyeCoach(TM) will be available in an institutional version designed for use at rehabilitation and medical centers.
Two Investment Opportunities in One Medical Device Company
ACCESSWIRE - Tue Jun 11, 11:15AM CDT
Vycor Medical (VYCO): A Buy One Get One Free Opportunity
Medical Device Maker Adds Patent for Vision Restoration Therapy
ACCESSWIRE - Tue Jun 04, 11:00AM CDT
Vycor Medical Inc. (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, has been significantly strengthening its patent portfolio over the past months. This week, the Company announced a new patent on its NovaVision® Vision Restoration Therapy (VRT™), bringing the total number of issued patents for NovaVision to 30 with nine pending.
Vycor's NovaVision(R) Unit Awarded Its 30th Patent
Marketwire - Mon Jun 03, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today it has been granted Japanese patent #JP5068770 for its NovaVision(R) technology. The patent covers methods for performing vision therapy by stimulating regions of the patient's field of vision that are technically "blind," but may still respond positively to repeated stimulus to eventually improve or recover vision in the blind field.
Vycor Issued Strategically Significant U.S. Patent for Its ViewSite(TM) Brain Access System (VBAS)
Marketwire - Wed May 29, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced that U.S. patent #12/545719, which relates to its ViewSite(TM) Brain Access System ("VBAS"), has been issued.
Innovation Marks Medical Device and Therapy Provider as Company to Watch
ACCESSWIRE - Tue May 28, 10:02AM CDT
Vycor Medical (VYCO) Poised to Become a Standard of Care in Neurosurgical Retraction and Neuro Visual Therapy
The Ohio State University Commences Key Comparative Study of Vycor's Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Mon May 20, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), a medical device company with a suite of FDA approved products, announced today that the Minimally Invasive Cranial Surgery Program at the Ohio State University (Columbus, OH) has commenced an animal study to evaluate a comparison of tissue damage when using Vycor's patented ViewSite(TM) Brain Access System ("VBAS") as compared to an open resection technique (using standard "blade retractors").
Vycor Announces Addition to Board of Directors
Marketwire - Fri May 03, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it is adding to the expertise on its board of directors with the appointment of Lowell Rush as independent director and Chairman of a newly-formed Audit Committee. At the same time Heather Vinas, who has remained on the Board since stepping down as President in May 2010, will depart the Board.
Vycor Develops New Device Targeted at the Pediatric Market
Marketwire - Wed May 01, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it has finalized the design prototypes of two new product variations of its existing VBAS product suite to be developed specifically for endoscopic work within the ventricles of the brain. Initially this device will be targeted at the pediatric market. The product was developed in close collaboration with a leading pediatric neurosurgeon. It is anticipated that the new products will be available commercially by the end of the year.
Vycor Adds Two Patents for Its New Spinal ViewSite(TM) Cervical Access System
Marketwire - Thu Apr 25, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today it has secured two new patents (2008-518369 and 11/993280) covering its Spinal ViewSite(TM) Cervical Access System (VCAS). The addition of these patents brings Vycor's total patent portfolio to 34 issued and 21 pending. The Company's Vycor Medical division now has 5 issued patents and 11 patents pending, and its NovaVision unit now has 29 issued patents and 10 patents pending.
Vycor Launches New Extension Arm for Its Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Mon Apr 15, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it has finalized the production and the U.S. commercial launch of an extension arm for its existing ViewSite(TM) Brain Access System ("VBAS") product range. It is currently anticipated that the extension arm will be available in Europe by the end of April.
Vycor Management Outlines Four Pronged Growth Strategy for Its Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Thu Apr 04, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) outlined today its multi-pronged strategy to continue to drive adoption for its Vycor Medical division's ViewSite(TM) Brain Access System ("VBAS").
Vycor Issued Hong Kong Patent for Its VBAS Minimally Invasive Brain Access System
Marketwire - Mon Mar 25, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced it has been issued patent number 10106385.8 for its ViewSite(TM) Brain Access System ("VBAS") for the Hong Kong market. Vycor has a distribution agreement in place with Devon Medical which covers Hong Kong and China.
Hospital Acceptance of Vycor's Patented VBAS Minimally Invasive Neurosurgical Device Continues to Accelerate
Marketwire - Wed Mar 13, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it continues to experience an increase in the number of hospitals where its patented ViewSite(TM) Brain Access System(R) ("VBAS") device has been approved for use. VBAS is now approved in over 100 hospitals in the U.S. and the number continues to grow. To date, more than 4,000 surgeries have been performed utilizing VBAS.
Vycor Medical, Inc. Announces Management Change
Marketwire - Fri Dec 21, 4:00PM CST
Vycor Medical, Inc. ("Vycor" or "Company") (OTCBB: VYCO) announced today that Richard Denness will resign as the Company's CEO effective December 31, 2012, and as a member of the Board of Directors effective immediately. Mr. Denness will remain as a consultant to the Company during a transition period. The Board will seek to appoint a successor CEO in due course.
Vycor Medical, Inc. President David Cantor to Be Interviewed Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Thu Jan 23, 6:15AM CST
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today that President David Cantor will interviewed live by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Vycor's NovaVision Unit Announces the Commercial Release of NeuroEyeCoach(TM) -- A Novel Saccadic Eye Training Therapy
Marketwire - Thu Jan 23, 6:00AM CST
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today that its wholly-owned subsidiary, NovaVision has launched the first commercial release of its new saccadic eye training therapy which will be marketed in the U.S. as NeuroEyeCoach(TM). The therapy is now available through the web site www.NeuroEyeCoach.com.
Vycor's NovaVision(R) Vision Restoration Therapy Awarded New Patent
Marketwire - Thu Oct 31, 7:31AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today it has been granted Australian patent # 2007277139 for its NovaVision(R) vision restoration technology. The new patent brings Vycor's total worldwide patent portfolio to 37 granted and 18 pending.
Vycor Medical Announces Planned Launch of First Commercially Available Internet-Based, Direct to the Patient Saccadic Eye Training Program
Marketwire - Tue Oct 15, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today its wholly-owned NovaVision subsidiary plans to launch a new "direct to the patient" saccadic eye training program to be marketed as NeuroEyeCoach(TM). The proprietary Internet-based program is expected to be commercially available by year-end 2013. Additionally, NeuroEyeCoach(TM) will be available in an institutional version designed for use at rehabilitation and medical centers.
Two Investment Opportunities in One Medical Device Company
ACCESSWIRE - Tue Jun 11, 11:15AM CDT
Vycor Medical (VYCO): A Buy One Get One Free Opportunity
Medical Device Maker Adds Patent for Vision Restoration Therapy
ACCESSWIRE - Tue Jun 04, 11:00AM CDT
Vycor Medical Inc. (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, has been significantly strengthening its patent portfolio over the past months. This week, the Company announced a new patent on its NovaVision® Vision Restoration Therapy (VRT™), bringing the total number of issued patents for NovaVision to 30 with nine pending.
Vycor's NovaVision(R) Unit Awarded Its 30th Patent
Marketwire - Mon Jun 03, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced today it has been granted Japanese patent #JP5068770 for its NovaVision(R) technology. The patent covers methods for performing vision therapy by stimulating regions of the patient's field of vision that are technically "blind," but may still respond positively to repeated stimulus to eventually improve or recover vision in the blind field.
Vycor Issued Strategically Significant U.S. Patent for Its ViewSite(TM) Brain Access System (VBAS)
Marketwire - Wed May 29, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite of FDA cleared products, announced that U.S. patent #12/545719, which relates to its ViewSite(TM) Brain Access System ("VBAS"), has been issued.
Innovation Marks Medical Device and Therapy Provider as Company to Watch
ACCESSWIRE - Tue May 28, 10:02AM CDT
Vycor Medical (VYCO) Poised to Become a Standard of Care in Neurosurgical Retraction and Neuro Visual Therapy
The Ohio State University Commences Key Comparative Study of Vycor's Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Mon May 20, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), a medical device company with a suite of FDA approved products, announced today that the Minimally Invasive Cranial Surgery Program at the Ohio State University (Columbus, OH) has commenced an animal study to evaluate a comparison of tissue damage when using Vycor's patented ViewSite(TM) Brain Access System ("VBAS") as compared to an open resection technique (using standard "blade retractors").
Vycor Announces Addition to Board of Directors
Marketwire - Fri May 03, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it is adding to the expertise on its board of directors with the appointment of Lowell Rush as independent director and Chairman of a newly-formed Audit Committee. At the same time Heather Vinas, who has remained on the Board since stepping down as President in May 2010, will depart the Board.
Vycor Develops New Device Targeted at the Pediatric Market
Marketwire - Wed May 01, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it has finalized the design prototypes of two new product variations of its existing VBAS product suite to be developed specifically for endoscopic work within the ventricles of the brain. Initially this device will be targeted at the pediatric market. The product was developed in close collaboration with a leading pediatric neurosurgeon. It is anticipated that the new products will be available commercially by the end of the year.
Vycor Adds Two Patents for Its New Spinal ViewSite(TM) Cervical Access System
Marketwire - Thu Apr 25, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today it has secured two new patents (2008-518369 and 11/993280) covering its Spinal ViewSite(TM) Cervical Access System (VCAS). The addition of these patents brings Vycor's total patent portfolio to 34 issued and 21 pending. The Company's Vycor Medical division now has 5 issued patents and 11 patents pending, and its NovaVision unit now has 29 issued patents and 10 patents pending.
Vycor Launches New Extension Arm for Its Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Mon Apr 15, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it has finalized the production and the U.S. commercial launch of an extension arm for its existing ViewSite(TM) Brain Access System ("VBAS") product range. It is currently anticipated that the extension arm will be available in Europe by the end of April.
Vycor Management Outlines Four Pronged Growth Strategy for Its Patented ViewSite(TM) Brain Access System (VBAS)
Marketwire - Thu Apr 04, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) outlined today its multi-pronged strategy to continue to drive adoption for its Vycor Medical division's ViewSite(TM) Brain Access System ("VBAS").
Vycor Issued Hong Kong Patent for Its VBAS Minimally Invasive Brain Access System
Marketwire - Mon Mar 25, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced it has been issued patent number 10106385.8 for its ViewSite(TM) Brain Access System ("VBAS") for the Hong Kong market. Vycor has a distribution agreement in place with Devon Medical which covers Hong Kong and China.
Hospital Acceptance of Vycor's Patented VBAS Minimally Invasive Neurosurgical Device Continues to Accelerate
Marketwire - Wed Mar 13, 7:30AM CDT
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it continues to experience an increase in the number of hospitals where its patented ViewSite(TM) Brain Access System(R) ("VBAS") device has been approved for use. VBAS is now approved in over 100 hospitals in the U.S. and the number continues to grow. To date, more than 4,000 surgeries have been performed utilizing VBAS.
Vycor Medical, Inc. Announces Management Change
Marketwire - Fri Dec 21, 4:00PM CST
Vycor Medical, Inc. ("Vycor" or "Company") (OTCBB: VYCO) announced today that Richard Denness will resign as the Company's CEO effective December 31, 2012, and as a member of the Board of Directors effective immediately. Mr. Denness will remain as a consultant to the Company during a transition period. The Board will seek to appoint a successor CEO in due course.
